Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study

20250 citationsJournal Articlegold Open Access

Authors

Ehsan Sadri · Visionary Pharmaceuticals (United States)

Casey Kopczynski · Alcon (United States)

Mohinder Merchea · Alcon (United States)

Abstract

In this study, additional IOP lowering was achievable when patients switched to netarsudil/latanoprost FDC after treatment with latanoprost alone or latanoprost with 1 or 2 additional agents. The once-daily administration of netarsudil/latanoprost FDC and reduced treatment burden for those on latanoprost combined with additional agents may prove more manageable for patients.

Topics & Keywords

Glaucoma and retinal disorders Cardiovascular Syncope and Autonomic Disorders Neurological Disorders and Treatments

Publication Details

Published in: Clinical ophthalmology

Volume Volume 19, pp. 175-186

DOI: 10.2147/opth.s491636

Field-Weighted Citation Impact: 0.00

Command Palette

Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study

Authors

Abstract

Topics & Keywords

Publication Details